帕博利珠单抗联合培美曲塞和卡铂治疗晚期非鳞状非小细胞肺癌的 疗效及对肿瘤标志物和细胞免疫功能的影响.

Objective:To explore the efficacy of carboplatin and pemetrexed combined with pablizumab in the treatment of advanced non squamous non-small cell lung cancer （NSCLC） and its effects on cellular immune function and tumor markers. Methods78 patients with advanced non squamous NSCLC who were admitted to the Affiliated Hospital of Xuzhou Medical University from October2018 to February 2021 were selected, they were divide into control group （n=39, received pemetrexed combined with carboplatin treatment） and combined group（n=39, received pembrolizumab treatment on the basis of control group） according to the random number table method. The efficacy, tumor marker levels, cellular immune function indicators, incidence of adverse reactions. Results: The objective response rate and disease control rate of combined group were higher than those of control group（P＜0. 05). There was no statistically significant difference in the incidence of adverse reactions between two groups（P＞0. 05). After treatment, the carcinoembryonic antigen （CEA）cytokeratin 19 fragment （CYFRA21-1）, and carbohydrate antigen 125 （CA125） levels decreased of two groups, and combined group were lower than those of control group （P＜0. 05). After treatment, the CD3+, CD4+, and CD4+/CD8+ decreased of two groups, but combined group were higher than those of control group （P＜0. 05). After treatment, the CD8+ increased of two groups, but combined group was lower than that of control group （P＜0. 05). Conclusion: Pabolizumab combined with pemetrexed and carboplatin in the treatment of advanced non-squamous NSCLC can effectively control disease progression, improve patient immune function, and reduce CEA, CYFRA21-1, and CA125 levels. [ABSTRACT FROM AUTHOR]